表紙
市場調查報告書

間質幹細胞 (MSC) :產品、技術的進步和各種用途

Mesenchymal Stem Cells - Advances & Applications 2019

出版商 BIOINFORMANT WORLDWIDE, LLC 商品編碼 234291
出版日期 內容資訊 英文 223 Pages
訂單完成後即時交付
價格
Back to Top
間質幹細胞 (MSC) :產品、技術的進步和各種用途 Mesenchymal Stem Cells - Advances & Applications 2019
出版日期: 2019年10月31日內容資訊: 英文 223 Pages
簡介

本報告提供間質幹細胞 (MSC)的市場調查,幹細胞及間質幹細胞 (MSC)的概要,各種類型,臨床性用途的發展與變化,臨床研究、臨床開發趨勢,已上市產品概要,各種用途、支援疾病趨勢,企業間的聯盟等的配合,主要企業、產品的簡介等彙整資料。

第1章 報告概要

第2章 簡介

第3章 尖端醫療醫藥品 (ATMP:ADVANCED THERAPY MEDICINAL PRODUCTS)

  • 主要的對象領域
  • 已上市ATMP的價格
  • FDA核准完畢ATMP
  • EC已核准ATMP

第4章 幹細胞:概要

  • 胚胎幹細胞 (ESC)
  • 誘導性多功能幹細胞 (iPSC)
  • 幹細胞來源的特殊化細胞的各種類型
  • 人體的幹細胞的各種類型
    • 人類胚胎幹細胞 (hESC)
    • EG細胞
    • 胎生幹細胞
    • 臍帶幹細胞
  • 成體幹細胞
    • 造血幹細胞 (HSC)
    • 間質幹細胞 (MSC)
    • 神經幹細胞 (NSC)
  • 各種幹細胞的特徵
  • 醫療的用途

第5章 間質幹細胞 (MSC):概要

  • MSC的新的名稱
  • MSC的功能
  • MSC的資源
  • hMSC的分離、培養
  • MSC的各種類型的特徵
  • hMSC可治療的慢性疾病
  • 成為MSC細胞治療的對象的一般疾病
  • 細胞治療中MSC的優點
  • MSC和其他幹細胞類型的比較
  • 自體MSC的缺點和同類MSC的優點
  • MSC的作用機制
  • 組織再生
  • 免疫修飾
  • MSC的製造

第6章 MSC的臨床性用途

  • GvHD
  • 心臟血管修復
  • 肝疾病
  • 骨/軟骨疾病的MSC
  • 已核准MSC產品
    • Cartistem
    • Stempeucel
    • MPC (Mesenchymal Precursor Cell):Mesoblast
    • Cupistem
    • Prochymal
    • AlloStem
    • Cellgram-AMI
    • Osteocel Plus
    • Trinity Evolution
    • CardioRel
    • Temcell
  • 含MSC的骨基材
    • 成本
    • 組織工程的整形外科產品候補
  • 已核准細胞治療產品的價格

第7章 幹細胞研究的出版、資金、專利

  • MSC相關科學論文
  • 全球幹細胞研究
  • NIH的MSC研究資金
  • 專利環境

第8章 MSC相關的臨床試驗:概要

  • 目前臨床試驗方案
  • MSC相關的臨床試驗的地區的佔有率
  • 臨床試驗的資源
  • 現在實驗中的支援疾病
  • 現行的臨床試驗
  • 臨床試驗的到目前為止的成果
  • 大學主導的主要的臨床實驗
  • 企業主導的主要的臨床實驗
  • 心血管疾病
  • 骨關節炎
  • 創傷治療
  • 肝疾病
  • 肺部疾病
  • 眼障礙
  • 腎障礙
  • 糖尿病
  • 移植物抗宿主病 (GvHD)
  • 發炎性腸道疾病
  • 多發性硬化症
  • 特定疾病的MSC臨床研究狀況
    • 移植物抗宿主病 (GvHD)
    • OA & RA
    • 發炎性呼吸道、肺部疾病
    • 多發性硬化症 (MS)
    • 發炎性腸道疾病 (IBD)
    • 基因改造MSC

第9章 聯盟的配合措施

第10章 市場分析

第11章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

EXECUTIVE SUMMARY

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially other cell types. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications.

Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth. MSCs are also well-suited for use in the exponential growth field of 3D printing, because of their capacity to form structural tissues. Growing attention is now being given to manufacturing technologies to support commercial-scale production of MSCs. Numerous market competitors are exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes, because these extracelluar “packages” represent a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.

As the most common stem cell type being used within regenerative medicine, there is huge potential for growth within the MSC market. There are more than one-hundred thousand scientific publications published about MSCs, as well as 900+ MSC clinical trials underway worldwide, including trials within the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number have reached Phase III, indicating that a limited number of MSC products have near-term market potential and the therapeutic market for MSCs remains early-stage. As of 2019, ten MSC-based products have received regulatory approvals, including nine cell therapy approvals and one tissue engineering approval. Population aging and an increasing prevalence of chronic disease are also driving interest in MSC-based therapies, with Google Trend data revealing that MSC searches are more than twice as common as the next most common stem cell type.

The main objectives of this report are to provide the reader with the following details:

  • A brief overview of the MSC industry
  • Biological factors secreted by MSCs
  • The manufacturing process of MSCs
  • Bioreactors used in the manufacture of MSCs
  • Microcarriers used for the expansion of MSCs
  • Cost of manufacturing autologous and allogeneic MSCs
  • Services offered by CMOs/CDMOs in the manufacture of MSCs
  • Major diseases addressed by MSCs in the ongoing clinical trials
  • Consumption of MSCs for academic research, clinical trials, product development, and exosome production
  • Brief account of approved cell therapy, gene therapy and tissue engineering products
  • Details of approved MSC-based cell therapeutics
  • Recent business developments pertinent to MSCs
  • Market size determinations for MSCs and MSC-based products
  • Details of products and product candidates developed by companies which are focusing exclusively on MSCs

Key questions answered in the report are:

  • How many MSC-based products have been approved so far?
  • Which countries have approved the products?
  • What are the various names within the scientific literature to indicate MSCs?
  • What are the functions of MSCs?
  • Which tissue sources yield MSCs?
  • What cell types do the MSCs differentiate into?
  • What are the soluble factors secreted by MSCs and what functions do the soluble factors perform?
  • What types of bioreactors are used for culturing and expanding the MSCs?
  • How much do allogeneic and autologous MSCs cost?
  • Which are the major cell manufacturing facilities in the U.S.?
  • Which are the major cell manufacturing facilities in Europe?
  • What are the major disease types addressed by MSCs in the ongoing clinical trials?
  • What is the current consumption of MSCs in academic and preclinical settings?
  • What is the current consumption and future demand for MSCs for developing cell therapies?
  • What MSC-based products have been approved?
  • What is the global market size for MSCs being used within academic research, preclinical studies, clinical trials and product development?
  • What is the global market size for the approved MSC-based therapeutics from 2018 to 2025?
  • Who are the leading competitors involved with developing MSC-based therapeutics?

As the first and only market research firm to specialize in the stem cell industry, BioInformant has a unique understanding of the rapidly evolving MSC Industry. Founded in 2006, BioInformant has collected more than 13 years of historical data on the industry, providing it with a robust historical database of data on which to make future market projections. Headquartered in Washington, DC, BioInformant is strategically positioned near industry lawmakers, the National Institutes of Health (NIH), U.S. FDA, and the Maryland Biotech Corridor, among other critical resources. In addition to leveraging an experienced team of analysts, this experience provides BioInformant with access to Key Opinion Leaders (KOLs) from across the MSC sector, including dozens of executives who were interviewed for this report.

As the world's first and only market research firm to specialize in the stem cell industry, BioInformant has conducted interviews with representatives from Cynata Therapeutics (first company to bring a iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (specializes in manufacturing tens of billions of MSCs in suspension bioreactors), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and more. With research cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine, BioInformant is your global leader in stem cell industry data.

Table of Contents

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary

2. MESENCHYMAL STEM CELLS (MSCS): AN INTRODUCTION

  • 2.1. The Various Names for MSCs
  • 2.3. Timeline of MSC Nomenclature
  • 2.4. Functions of MSCs
  • 2.5. Sources of MSCs
    • 2.5.1. Bone Marrow-Derived MSCs (BM-MSCs)
    • 2.5.2. Adipose-Derived MSCs (AD-MSCs)
      • 2.5.2.1. Comparison of Yield by Isolation Method
    • 2.5.3. Umbilical Cord-Derived MSCs (UC-MSCs)
  • 2.6. Cell Surface Markers in MSCs
  • 2.7. In Vitro Differentiation Potential of MSCs
  • 2.8. Soluble Factors Secreted by MSCs

3. MANUFACTURE OF MESENCHYMAL STEM CELLS

  • 3.1. Methods of Isolation of MSCs
  • 3.2. From Conventional Cultures to Bioreactors
    • 3.2.1. Monolayer Culture Systems
    • 3.2.2. Bioreactor-Based Cell Expansion
      • 3.2.2.1. Stirred Tank Bioreactor
      • 3.2.2.2. Rocking Bioreactor
      • 3.2.2.3. Hollow Fiber Bioreactors
      • 3.2.2.4. Fixed-Bed Bioreactors
    • 3.2.3. Main Features of the Commercial Bioreactors
    • 3.2.4. Microcarriers used for the Expansion of MSCs
  • 3.3. Downstream Processing of hMSCs
    • 3.3.1. Cell Detachment and Separation
    • 3.3.2. Cell Washing and Concentration
    • 3.3.3. Safety and Potency Assays
  • 3.4. Surface Markers for Identification
  • 3.4. MSC Manufacturing Bottlenecks and Solutions

4. COMPARISON OF AUTOLOGOUS & ALLOGENEIC CELL MANUFACTURING

  • 4.1. Manufacturing of Allogeneic Cells
  • 4.2. Cost Differential
  • 4.3. Donor Screening and Testing
  • 4.4. Release Testing
  • 4.5. Comparison of the Two Business Models
    • 4.5.1. Risk of Immune Reaction
    • 4.5.2. Risk of Cross Contamination
    • 4.5.3. Commercially Attractive Option

5. COST OF CELL MANUFACTURING

  • 5.1. Cost Breakdown
  • 5.2. Opportunities for Cost Reduction
  • 5.3. Partial Automation vs. Full Automation
  • 5.4. Partial Automation: Most Attractive Option

6. CONTRACT MANUFACTURING OF MSCs

  • 6.1. CMOS
  • 6.2. CDMOs
    • 6.2.1. Opportunities for MSC Equipment and Media System Developers
  • 6.3. Leading Cell Therapy CMOS
  • 6.4. Global Cell Manufacturing Capacity

7. DISEASES ADDRESSED BY MSCS IN CLINICAL TRIALS

  • 7.1. MSCs in Hematological Diseases and Graft-versus-Host Diseases (GvHD)
  • 7.2. MSCs in Cardiovascular Diseases
  • 7.3. MSCs in Neurological Diseases
  • 7.4. MSCs in Bone and Cartilage Diseases
  • 7.5. MSCs in Lung, Liver, and Kidney Diseases

8. CLINICAL TRIALS LANDSCAPE OF MSCS

  • 8.1. Phases of Studies
  • 8.2. Sources of Cells for Clinical Trials using MSCs
  • 8.3. Share of Autologous vs. Allogeneic Transfusions of MSCs in Clinical Trials
  • 8.4. MSC-Based Clinical Trial Location by Geography

9. CONSUMPTION OF MSCS

  • 9.1. Consumption of MSCs within Cardiac Applications
  • 9.2. Dosing of MSCs within Cell Therapy and Tissue Engineering
  • 9.3. Rates of MSCs Scientific Publications
  • 9.4. Frequency of MSC Online Searches (Google Trends)
  • 9.5. Pricing of MSCs
  • 9.6. Disruptive Technologies to Threaten the Demand for MSCs)

10. APPROVED CELL-BASED MEDICINAL PRODUCTS

  • 10.1. Approved Cell-Based Medicinal Products by Region/Country
  • 10.2. Approved Cell-Based Medicinal Products by Therapy Type
  • 10.3. Major Cell Types used in Approved Cell-Based Medicinal Products
  • 10.4. Price of Cell-Based Therapies
  • 10.5. MSC-Based Medicinal Products
    • 10.5.1. Alofisel
    • 10.5.2. Chondrocytes-T-Ortho-ACI
    • 10.5.3. Spherox
    • 10.5.4. Ossgrow
    • 10.5.5. Stempeucel
    • 10.5.6. Prochymal (remestemcel-L)
    • 10.5.7. Temcell HS
    • 10.5.8. Neuronata-R
    • 10.5.9. Cupistem
    • 10.5.10. Cellgram-AMI

11. RECENT BUSINESS DEVELOPMENTS IN MSCS AND RELATED SECTORS

  • 11.1. Novartis to Acquire CELLforCURE
  • 11.2. Novartis' Agreement with Cellular Biomedicine Group
  • 11.3. AveXis to Acquire a Biologics Manufacturing Campus in Longmont
  • 11.4. The Leasing of Hoofddorp Facility by Kite Pharma
    • 11.4.1. Other Additions to Kite Pharma
  • 11.5. Celgene's New Manufacturing Center
  • 11.6. Roche to Acquire Spark Therapeutics
  • 11.7. Astella Pharma's New Facilities
  • 11.8. Novo Nordisk to have a New Facility in Fremont
  • 11.9. Catalent to Acquire Paragon Bioservices
  • 11.10. Paragon's New Facility
  • 11.11. Thermo Fisher Scientific to Acquire the CDMO, Brammer Bio
  • 11.12. Lonza's Acquisition of Octane Biotech
  • 11.13. Lonza Installing Multiple Cell Therapy Suites
  • 11.14. Fujifilm's New GMP Production Facility
  • 11.15. Bluebird bio's New Facility in Durham
  • 11.16. Allogene Therapeutics' Facility in Newark
  • 11.17. Rubius Therapeutics' Facility in Rhode Island
  • 11.18. Hitachi Chemical to Acquire Apceth Biopharma

12. MARKET ANALYSIS

  • 12.1. Global Market for Mesenchymal Stem Cells (MSCs)
  • 12.2. Global Market for MSCs and MSC-Based Therapeutics

13. COMPANY PROFILES

  • 13.1. AlloSource, Inc
    • 13.1.1. ProChondrix CR
    • 13.1.2. AlloFuse (Cellular Allograft Matrix)
  • 13.2. American Type Culture Collection (ATCC)
    • 13.2.1. Stem Cell Products
  • 13.3. Anterogen, Co., Ltd
    • 13.3.1. Cupistem Injection
    • 13.3.2. Queencell
  • 13.4. Athersys, Inc
    • 13.4.1. MultiStem
  • 13.5. BioCardia, Inc.
  • 13.6. Brainstorm Cell Therapeutics, Inc.
    • 13.6.1. Autologous MSC-NTF Cells
  • 13.7. CellGenix Technologie Transfer GmbH
    • 13.7.1. Products
  • 13.8. Celltex Therapeutics Corporation
    • 13.8.1. Banking Services
    • 13.8.2. Therapies
  • 13.9. Cesca Therapeutics, Inc.
    • 13.9.1. CellXpress (CXP)
    • 13.9.2. CXP + BioArchive
    • 13.9.3. PXP
    • 13.9.4. AutoXpress (AXP)
    • 13.9.5. CAR-TXpress
  • 13.10. Cynata Therapeutics Ltd.
    • 13.10.1. Cymerus Platform
  • 13.11. CO.DON AG
    • 13.11.1. Spherox
  • 13.12. Corestem, Inc
    • 13.12.1. NeuroNATA-R
  • 13.13. Cytori Therapeutics, Inc
    • 13.13.1. Cytori Cell Therapy
  • 13.14. Escape Therapeutics, Inc
  • 13.15. HemaCare Corporation
    • 13.15.1. Products
  • 13.16. Invitrx Therapeutics, Inc
    • 13.16.1. Invitra CBSC
    • 13.16.2. Invitra WJ-C
  • 13.17. iXCells Biotechnologies
    • 13.17.1. Products
  • 13.18. JCR Pharmaceuticals, Co., Ltd.
    • 13.18.1. STEMCELL HS Inj
  • 13.19. MEDIPOST, CO., Ltd.
    • 13.19.1. CARTISTEM
    • 13.19.2. PNEUMOSTEM
    • 13.19.3. NEUROSTEM
  • 13.20. Mesoblast Ltd
    • 13.20.1. Product Candidates
  • 13.21. NuVasive, Inc
    • 13.21.1. Osteocel Plus
  • 13.22. Orthocell, Ltd
    • 13.22.1. Ortho-ATI
    • 13.22.2. Ortho-ACI
    • 13.22.3. CelGro
  • 13.23. Osiris Therapeutics, Inc
    • 13.23.1. Grafix PRIME & GrafixPL PRIME
    • 13.23.2. Stravix
    • 13.23.3. Cartiform
    • 13.23.4. BIO
    • 13.23.5. Prochymal
  • 13.24. Pharmicell, Co., Ltd
    • 13.24.1. Cellgram-AMI
  • 13.25. Pluristem Therapeutics, Inc.
    • 13.25.1. PLX Products
  • 13.26. Regeneus, Ltd.
  • 13.27. Reliance Life Sciences
    • 13.27.1. Products
  • 13.28. RoosterBio, Inc.
    • 13.28.1. Products
  • 13.29. San-Bio, Inc.
  • 13.30. ScienCell Research Laboratories, Inc
    • 13.30.1. Products
  • 13.31. StemBioSys, Inc
    • 13.31.1. CELLvo Matrix Technology
    • 13.31.2. CELLvo Cells Technology
  • 13.32. STEMCELL Technologies Canada, Inc
    • 13.32.1. Products
  • 13.33. Stempeutics Research Pvt., Ltd.
    • 13.33.1. Stempeucel
    • 13.33.2. Stempeutron
    • 13.33.3. Stempeucare (Cutisera)
  • 13.34. Takeda Pharmaceuticals U.S.A. Inc
    • 13.34.1. Alofisel

14. MSC-DERIVED EXOSOMES AND EVs

  • 14.1. Characteristics of MSC-Derived Exosomes
  • 14.2. Advantages of MSC-Derived Exosomes
  • 14.3. Therapeutic Effects of MSC-Derived Exosomes
  • 14.4. Characterization of MSC-Derived Exosomes
  • 14.5. Patent Analysis for MSC-Derived Exosomes

15. REGULATORY OVERSIGHT OF MSC THERAPEUTICS

List of Figures

  • Figure 3.1: Monolayer Culture Systems
  • Figure 3.2: Stirred Tank Bioreactor
  • Figure 3.3: Rocking Bioreactor
  • Figure 3.4: Hollow Fiber Bioreactors
  • Figure 3.5: Fixed-Bed Bioreactor
  • Figure 4.1: Annual Cost of Manufacturing Autologous and Allogeneic Cells
  • Figure 5.1: Cost of Goods (CoG) Breakdown in Autologous Cell Manufacturing
  • Figure 5.2: Impact of HeadCount on Overall COG per Batch
  • Figure 5.3: CoG Breakdown in Partially-Automated Cell Manufacturing
  • Figure 5.4: CoG Breakdown in Fully-Automated Cell Manufacturing
  • Figure 8.1: Major Diseases Addressed by MSCs in Clinical Trials
  • Figure 8.2: The Percent Share of MSC-Based Studies under Different Phases
  • Figure 8.3: Percent Share of Sources of Cells for Clinical Trials using MSCs
  • Figure 8.4: Share of Autologous vs. Allogeneic Transfusions of MSCs in Clinical Trials
  • Figure 8.5: MSC-Based Clinical Trial Location by Geography
  • Figure 10.1: Approved Cell-Based Medicinal Products by Region/Country
  • Figure 10.2: Approved Cell-Based Medicinal Products by Therapy Type
  • Figure 10.3: Approved Cell-Based Medicinal Products by Cell Type
  • Figure 12.1: Global Market for Mesenchymal Stem Cells by Geography, 2018-2025
  • Figure 12.2: Global Market for MSCs and MSC-Based Therapeutics, 2018-2025

List of Tables

  • Table 2.1: Timeline of MSC Nomenclature
  • Table 2.2: Adult Sources of MSC Isolation
  • Table 2.3: Fetal Sources of MSCs
  • Table 2.4: Advantages and Disadvantages of Bone Marrow-Derived MSCs
  • Table 2.5: Advantages and Disadvantages of Adipose-Derived MSCs
  • Table 2.6: Comparison of Yield and Viability of AD-MSCs by Isolation Methods
  • Table 2.7: Advantages and Disadvantages of Umbilical Cord-Derived MSCs
  • Table 2.8: Positive and Negative Markers for MSCs Derived from Different Sources
  • Table 2.9: In vitro Differentiation Potential of MSCs
  • Table 2.10: Soluble Factors Secreted by MSCs
  • Table 2.11: Biological Functions of Soluble Factors Secreted by MSCs
  • Table 3.1: MSC Discovery, Characterization, and Clinical Applications
  • Table 3.2: Methods of Isolation and Required Culture Media
  • Table 3.3: Monolayer Culture Systems and Bioreactors
  • Table 3.4: Main Features of Commercially Available Bioreactors
  • Table 3.5: Microcarriers used in Bioreactors
  • Table 3.6: Basic Assays for MSCs
  • Table 3.7: Surface Markers Present in MSCs and Fibroblasts
  • Table 4.1: Comparison of Allogeneic and Autologous Therapies
  • Table 5.1: Cost of Goods in the Manufacture of Cells
  • Table 5.2: CoG Breakdown in Partially-Automated Cell Manufacturing
  • Table 5.3: CoG Breakdown in Fully-Automated Cell Manufacturing
  • Table 5.4: Higher Throughput in Partly Automated Facilities
  • Table 6.1: Global Distribution of CMOS
  • Table 7.1: Examples of On-Going MSC-Based Clinical Trials Addressing GvHD
  • Table 7.1: Examples of On-Going MSC-Based Clinical Trials Addressing Heart Diseases
  • Table 7.3: MSC-Based Clinical Trials Addressing Neurological Diseases
  • Table 7.4: MSC-Based Clinical Trials to Address Orthopedic Disorders
  • Table 7.9: MSC-Based Clinical Trials Addressing Liver Disorders
  • Table 8.1: Major Diseases Addressed by MSCs in Clinical Trials
  • Table 10.1: Approved Cell-Based Medicinal Products
  • Table 10.2: Prices of Cell and Gene-Based Therapies
  • Table 10.3: MSC-Based Approved Products
  • Table 12.1: Global Market for MSCs by Geography, 2018-2025
  • Table 12.2: Global Market for MSCs and MSC-Based Therapeutics, 2018-2025
  • Table 13.1: Athersy's Product Candidates using MultiStem Cells
  • Table 13.2: BioCardia's Product Pipeline
  • Table 13.3: Brainstorm's Product Pipeline
  • Table 13.4: Cynata's Product Candidates
  • Table 13.5: Corestem's Product/Product Candidates
  • Table 13.6: Escape Therapeutics' Product Pipeline
  • Table 13.7: Mesoblast's MSC-Based Products/Product Candidates
  • Table 13.8: Pharmicell's MSC-Based Products in Development
  • Table 13.9: Pluristem's Product Pipeline
  • Table 13.10: Regeneus' Human Health Development Pipeline
  • Table 13.11: San-Bio's Product Pipeline
  • Table 13.12: Stempeutics' Product Candidates

Companies Mentioned:

  • AdiCyte
  • AdiSave
  • Alliancells Bioscience Corporation Ltd.
  • AlloSource Inc.
  • American CryoStem Corporation
  • Ankara University
  • Anterogen Co., Ltd.
  • Apceth Biopharma GmbH
  • Asahi Glass. Co.
  • Astarte Biologics Inc.
  • AstraZeneca
  • Athersys Inc.
  • Big Pharma
  • BioCardia Inc.
  • BioRestorative Therapies Inc.
  • Bone Therapeutics SA
  • Brainstorm Cell Therapeutics
  • Cairo University
  • Caladrius Biosciences Inc.
  • Capricor Therapeutics Inc.
  • Celal Bayar University
  • Cell Applications Inc.
  • Cell Cure Neurosciences Ltd.
  • Cell Therapies Pty Ltd.
  • Cell Therapy Ltd.
  • CellGenix Technologie Transfer GmbH
  • CellProthera SAS
  • Celltex Therapeutics Corporation
  • Cellular Biomedicine Group Ltd.
  • Cellular Dynamics International Inc.
  • Celprogen Inc.
  • Celvive Inc.
  • Celyad SA
  • Cesca Therapeurics Inc.
  • Cyagen Biosciences Inc.
  • Cynata Therapeucics Ltd.
  • Cytori Therapeutics Inc.
  • Daiichi Sankyo
  • Escape Therapeutics Inc.
  • Fujifilm
  • Fujifilm Holdings
  • Future Health BioBank
  • Gamida Cell Ltd.
  • Gilead
  • GlaxoSmithKline (GSK)
  • GSK
  • Healios K.K.
  • Hitachi
  • Intercytex Ltd.
  • International Stem Cell Corp.
  • Invitrx Therapeutics Inc.
  • J&J
  • JCR Pharmaceuticals Co., Ltd.
  • Johnson & Johnson
  • Kadimastem Ltd.
  • Kiadis Pharma N.V.
  • Kite Pharma Inc.
  • Kolon Life Sciences
  • Life Sciences Inc.
  • Living Cell Technologies Ltd.
  • Lonza Group Ltd.
  • Magenta Therapeutics Inc.
  • Medeor Therapeutics Inc.
  • Medipost Co., Ltd.
  • Mesoblast Ltd.
  • Miltenyl Biotec
  • Mitsubishi Tanabe
  • Neuralstem Inc.
  • Nikon
  • Novartis
  • NuVasive Inc.
  • Octane Biotech Inc.
  • Ono Pharmaceuticals
  • Organogenesis Inc.
  • Orthofix International N.V.
  • Osiris Therapeutics Inc.
  • OxStem Ltd.
  • Pfizer
  • PharmaCell B.V.
  • Pharmicell Co. Ltd.
  • Pluristem Therapeutics Inc.
  • Precious Cells International Ltd.
  • Promethera Biosciences S.A.
  • Provia Laboratories, LLC
  • Regen BioPharma Inc.
  • Regeneus Ltd.
  • Reliance Life Sciences Pvt. Ltd.
  • Reneuron Group plc
  • RepliCel Life Sciences
  • ReproCELL Inc.
  • Roche
  • SanBio Life Sciences
  • Sangamo
  • Sanofi
  • Scinow Biotechnology Co., Ltd.
  • Shenzhen Hometcorn Biotechnology Co., Ltd.
  • Shiseido Co., Ltd.
  • Stemedica Cell Technologies Inc.
  • StemGen Therapeutics
  • Steminent Biotherapeutics
  • Stempeutics Research Pvt. Ltd.
  • Stratatech Corp.
  • Sumitomo
  • Takeda Pharmaceuticals
  • ThermoFischer Scientific Inc.
  • TiGenix N.V.
  • Tissue Regeneration Systems by DePuy Synthes Products (J&J)
  • U.S. Stem Cell Inc.
  • University Hospital of Liege
  • University of Jordan
  • University of Sao Paulo
  • Vericel Corporation
  • ViaCyte Inc.
  • Xintea AB
  • Zen-Bio Inc.
Back to Top